Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
2.
Heliyon ; 8(8): e10147, 2022 Aug.
Article in English | MEDLINE | ID: mdl-36033325

ABSTRACT

This work was carried out on the lateritic soils of Mbé in the Adamawa region of Cameroon. For this study, twenty (20) soil samples were taken from four (04) sites (Kabaa, Ndom, Mbé Norwegian camp, and Nyéssé). To assess their suitability for the production of compressed earth bricks, physical parameters were obtained by geotechnical tests to determine particle size distribution, water content, atterbergs limits, specific gravity, methylene blue value, maximum dry density (MDD), and optimum moisture content (OMC). Chemical and mineralogical properties were obtained by X-ray fluorescence and X-ray diffraction, respectively, followed by the determination of technological parameters (water absorption and mechanical properties) on compressed earth brick specimens. The results show that the studied lateritic soils contain mainly sand (52.8-90.3 wt%) and clay particles (8.4-42.1 wt%), gravel particles are slightly represented (1.1-16.3 wt%). The plasticity index of the studied materials is average (5-38%), about their methylene blue values (1-5), these soils correspond to clayey-silty soils. The materials studied are classified by the USCS as clayey sands/silty clays; according to the Highway Research Board (HRB), they are classified as A-7-5 or A-7-6 clayey soils with group index of 1 for Kabaa, 7 for Ndom, 9 for Mbé Norwegian Camp, and 12 for Nyéssé. These soils are rich in silica (SiO2, 62.6-78.1 wt%), followed by aluminum (Al2O3, 11.8-18.2 wt%) and iron oxides (Fe2O3, 3.2-8.1 wt%); other oxides are in lower proportions (<1 wt%). The mineralogical content consists mainly of clay minerals such as kaolinite, illite, smectite (montmorillonite), and non-clay minerals such as quartz, muscovite, biotite, gibbsite, and hematite. The bulk density and mechanical properties of the specimens are within the standard NC 102-115 (2007) of compressed earth bricks (CEB), which recommends minimum compressive strengths of 2 Mpa for unstabilized CEB and 4 Mpa for stabilized CEB. Water absorption of CEB and physical parameters of soils have a significant impact on the mechanical behavior of CEB. According to the test results, Mbe lateritic soils are suitable for engineering applications in the production of stabilized compressed earth bricks.

3.
Neurobiol Dis ; 36(1): 213-22, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19635563

ABSTRACT

We have previously shown that docosahexaenoic acid (DHA) significantly reduced L-Dopa-induced dyskinesia (LID) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys (Samadi et al., Ann. Neurol. 59:282-288, 2006). In the present study, we measured for the first time mRNA levels of Nur77, an orphan nuclear receptor that participates to adaptive and/or aberrant dopamine-related behaviors, and retinoid X receptor gamma1 (RXRgamma1), a putative brain receptor for DHA and transcriptional partner of Nur77, in MPTP monkeys treated with L-Dopa and DHA. The RXRgamma1 mRNA is strongly expressed in monkey caudate nucleus and putamen, but no change in levels of RXRgamma1 was observed following MPTP and L-Dopa treatments. On the other hand, denervation reduced Nur77 mRNA levels, whereas chronic L-Dopa treatment strongly induced Nur77 transcripts. These modulations are taking place in substance P positive cells and are associated with both caudate-putamen matrix and striosome compartments. Interestingly, combination of L-Dopa with DHA further increases Nur77 mRNA levels in the anterior caudate-putamen, and mainly in striosomes. This is accompanied by a significant inverse correlation between Nur77 mRNA levels and dyskinetic scores. Taken together, our results show that Nur77 expression is modulated following dopamine denervation and chronic L-Dopa therapy in a non-human primate model of Parkinson's disease, and suggest that strong modulation of Nur77 expression might be linked to a reduced risk to develop LIDs.


Subject(s)
Antiparkinson Agents/adverse effects , Docosahexaenoic Acids/pharmacology , Dyskinesia, Drug-Induced , Levodopa/adverse effects , Nuclear Receptor Subfamily 4, Group A, Member 1/genetics , RNA, Messenger/metabolism , Acetylcholinesterase/metabolism , Analysis of Variance , Animals , Autoradiography/methods , Brain/drug effects , Brain/metabolism , Cocaine/analogs & derivatives , Cocaine/metabolism , Disease Models, Animal , Drug Interactions , Dyskinesia, Drug-Induced/drug therapy , Female , Iodine Isotopes/metabolism , MPTP Poisoning/drug therapy , MPTP Poisoning/pathology , Macaca fascicularis , Protein Binding/drug effects , Statistics as Topic
4.
Contraception ; 79(3): 167-77, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19185668

ABSTRACT

BACKGROUND: In the fall of 2007, the controversy about the contraceptive use of depot-medroxyprogesterone acetate (DMPA) and its potential impact on skeletal health reached the media in the province of Quebec, Canada, thereby becoming a matter of concern for the lay public and physicians. In order to discuss this subject openly, the National Institute of Public Health of Quebec (INSPQ) organized a scientific meeting on February 15, 2008, with targeted physicians delegated by their medical associations in the fields of general practice, obstetrics and gynaecology, rheumatology, orthopaedic surgery, physiatry and endocrinology. STUDY DESIGN: Participants reviewed the scientific literature using the study classification method according to the level of evidence, reviewed published guidelines of medical societies and organizations on the subject and reached a consensus position. This manuscript presents a review of the literature and describes the consensus position of the targeted medical associations. RESULTS: The consensus position adopted by all the targeted medical associations determined that DMPA was a cost-effective contraceptive option that must be considered in the light of the clinical situation and preference of each woman. Candidates for injectable contraception should be informed that the use of DMPA is associated with a slight decrease in bone mineral density (BMD), which is largely, if not completely, reversible. There should not be an absolute limit to the length of time that the DMPA contraceptive is used, regardless of the woman's age. Monitoring BMD is not recommended among users of DMPA for contraceptive purposes. Finally, the consensus statement declared that, although supplements of calcium and vitamin D are beneficial for skeletal health for women in general, such supplementation should not be recommended solely based on a woman's use of DMPA. CONCLUSION: Given the scientific evidences, DMPA use remains a valid contraceptive option for women. Its potential impact on BMD must be balanced against the significant individual, familial and social consequences of unintended pregnancy.


Subject(s)
Bone Density/drug effects , Contraception/standards , Contraceptive Agents, Female/adverse effects , Medroxyprogesterone Acetate/adverse effects , Osteoporosis/epidemiology , Canada/epidemiology , Delayed-Action Preparations , Female , Fractures, Bone/epidemiology , Humans , Pregnancy , Pregnancy Rate
5.
Biol Psychiatry ; 60(6): 538-47, 2006 Sep 15.
Article in English | MEDLINE | ID: mdl-16893530

ABSTRACT

BACKGROUND: Transcription factors of the Nur family (Nurr1, Nur77, and Nor-1) are orphan nuclear receptors closely associated with dopamine neurotransmission in the central nervous system. Nur77 expression is strongly modulated by antipsychotic and ant-parkinsonian drugs in dopaminoceptive brain areas. However, the role of Nur77 in dopamine neuron activity and turnover remains elusive. METHODS: We compared various behavioral and biochemical parameters between Nur77 knockout -/- and wild-type +/+ mice in basal and haloperidol-challenged conditions. RESULTS: We report here that Nur77-deficient mice display enhanced spontaneous locomotor activity, greater sensitivity to a small dose of the dopamine D2 receptor agonist quinpirole acting mainly at autoreceptor sites, and higher levels of the dopamine metabolite DOPAC relative to wild-type mice. Dopamine turnover disturbances are also found after acute challenge with haloperidol, a dopamine D2 receptor antagonist. These alterations are associated with increased tyrosine hydroxylase expression and activity, and reduced catechol-O-methyltransferase expression. CONCLUSION: Taken together, these results are consistent with the involvement of Nur77 in dopamine neuron biochemical activity and dopamine turnover.


Subject(s)
Brain Chemistry/genetics , DNA-Binding Proteins/deficiency , Dopamine/metabolism , Neurons/metabolism , Receptors, Cytoplasmic and Nuclear/deficiency , Receptors, Steroid/deficiency , Transcription Factors/deficiency , Analysis of Variance , Animals , Behavior, Animal/physiology , Catechol O-Methyltransferase/genetics , Catechol O-Methyltransferase/metabolism , Corpus Striatum/cytology , Corpus Striatum/metabolism , DNA-Binding Proteins/genetics , Dopamine Plasma Membrane Transport Proteins/metabolism , Electrochemistry/methods , Exploratory Behavior/physiology , Gene Expression Regulation/genetics , Immunohistochemistry/methods , In Situ Hybridization/methods , Levodopa/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Motor Activity/genetics , Nuclear Receptor Subfamily 4, Group A, Member 1 , Protein Binding/drug effects , Protein Binding/physiology , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Steroid/genetics , Transcription Factors/genetics , Tyrosine 3-Monooxygenase/genetics , Tyrosine 3-Monooxygenase/metabolism
6.
J Neurochem ; 96(1): 160-70, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16269007

ABSTRACT

Preferential neurodegeneration of dopaminergic neurons in the ventral substantia nigra of the midbrain is a hallmark of Parkinson's disease. The homeobox transcription factor Pitx3 is similarly and selectively expressed in the same neurons. Pitx3 deficiency in a natural mouse mutant, the aphakia mouse, was correlated with the loss of these neurons and with a deficit in locomotor activity. We now report that the locomotor deficit of aphakia mice is established by 40 days of age and that it can be rescued by injection of l-dopa. We further show that downstream striatal correlates of the midbrain neuronal losses in aphakia mice, as assessed by dopamine transporter binding and expression of dopamine receptors, enkephalin, dynorphin and neurotensin, are highly similar to neuroadaptive responses observed following rapid neurodegeneration induced by neurotoxin administration in adult animals or following the progressive neurodegenerative processes as seen in Parkinson patients. Taken collectively, these data support the idea that the aphakia mice represent a selective model of dopaminergic deficiency that closely resembles the midbrain and striatal neuropathology associated with Parkinson's disease, and this suggests that these mice are a good model to assess therapies for Parkinson's disease as well as to understand the susceptibility of these neurons to neurodegeneration.


Subject(s)
Antiparkinson Agents/therapeutic use , Aphakia/drug therapy , Homeodomain Proteins/physiology , Levodopa/therapeutic use , Locomotion/physiology , Neostriatum/pathology , Parkinson Disease/drug therapy , Transcription Factors/physiology , Adaptation, Physiological , Animals , Aphakia/genetics , Aphakia/pathology , Autoradiography , Biomarkers , Homeodomain Proteins/genetics , In Situ Hybridization , Locomotion/drug effects , Mice , Mice, Inbred C57BL , Neostriatum/physiopathology , Neuropeptides/metabolism , Parkinson Disease/metabolism , Phenotype , Receptors, Dopamine/drug effects , Receptors, Dopamine/physiology , Receptors, Dopamine D2/physiology , Transcription Factors/genetics
7.
J Neuropathol Exp Neurol ; 64(11): 936-47, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16254488

ABSTRACT

Although oral administration of L-Dopa remains the best therapy for Parkinson disease, its long-term administration causes the appearance of abnormal involuntary movements such as dyskinesia. Although persistent striatal induction of some genes has already been associated with such pathologic profiles in hemiparkinsonian rats, molecular and cellular mechanisms underlying such long-term adaptations remain to be elucidated. In this study, using a rat model of L-Dopa-induced dyskinesia, we report that activity regulated cytoskeletal (Arc)-associated protein is strongly upregulated in the lesioned striatum and that the extent of its induction further varies according to the occurrence or absence of locomotor sensitization. Moreover, Arc is preferentially induced, along with FosB, nur77, and homer-1a, in striatonigral neurons, which express mRNA encoding the precursor of dynorphin. Given the likely importance of Arc in the regulation of cytoskeleton during synaptic plasticity, its upregulation supports the hypothesis that a relationship exists between cytoskeletal modifications and the longlasting action of chronically administrated L-Dopa.


Subject(s)
AIDS-Related Complex/metabolism , Antiparkinson Agents/administration & dosage , Dyskinesia, Drug-Induced/etiology , Levodopa/administration & dosage , Neurons/physiology , Substantia Nigra/cytology , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology , AIDS-Related Complex/genetics , Adrenergic Agents/adverse effects , Amphetamine/pharmacology , Analgesics, Non-Narcotic/pharmacology , Animals , Antiparkinson Agents/adverse effects , Behavior, Animal , Carrier Proteins/genetics , Central Nervous System Stimulants/pharmacology , Corpus Striatum/cytology , Disease Models, Animal , Drug Interactions , Dynorphins/genetics , Dyskinesia, Drug-Induced/metabolism , Functional Laterality , Homer Scaffolding Proteins , Immunohistochemistry/methods , In Situ Hybridization/methods , Levodopa/adverse effects , Male , Motor Activity/drug effects , Naloxone/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Neurons/drug effects , Oxidopamine/adverse effects , Protein Precursors/genetics , Proto-Oncogene Proteins c-fos/genetics , Proto-Oncogene Proteins c-fos/metabolism , Rats , Rats, Wistar , Stereotyped Behavior/drug effects , Time Factors , Tyrosine 3-Monooxygenase/metabolism , Up-Regulation/drug effects
8.
Neuropsychopharmacology ; 27(2): 301-8, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12093604

ABSTRACT

The hypothermia produced by 5-HT1A agonists had initially been claimed to be caused by the activation of cell body 5-HT1A autoreceptors resulting in decreased 5-HT transmission in laboratory animals. In order to address this issue in humans, 12 healthy volunteers underwent a dietary tryptophan depletion paradigm to decrease 5-HT availability, under double-blind conditions, during which body temperature was monitored following oral administration of the 5-HT1A agonist buspirone (30 mg). In addition, plasma prolactin and growth hormone evaluations, two responses that are mediated via the direct activation of postsynaptic 5-HT1A receptors, were determined. The hypothesis was that if responses are mediated by decreased transmission at postsynaptic 5-HT1A receptors, resulting from dampened 5-HT release as a consequence of 5-HT1A autoreceptors activation, then responses to the exogenous 5-HT1A agonist should be attenuated when 5-HT availability has been markedly decreased beforehand. Buspirone produced the same significant increase in prolactin and growth hormone in the tryptophan-depleted state as in the control condition. Similarly, the degree of hypothermia produced by buspirone was not significantly different in the two experimental conditions. In conclusion, these results strongly suggest that the hypothermia and the increases in prolactin and growth hormone produced by buspirone are attributable to the enhanced activation of postsynaptic 5-HT1A receptors, and not to a decrease in 5-HT transmission resulting from the activation of the 5-HT1A cell body autoreceptors on 5-HT neurons.


Subject(s)
Autoreceptors/drug effects , Brain/drug effects , Buspirone/adverse effects , Hypothermia/chemically induced , Presynaptic Terminals/drug effects , Receptors, Serotonin/drug effects , Serotonin Receptor Agonists/adverse effects , Serotonin/biosynthesis , Adult , Autoreceptors/metabolism , Body Temperature/drug effects , Body Temperature/physiology , Brain/metabolism , Brain/physiopathology , Cross-Over Studies , Double-Blind Method , Growth Hormone/blood , Growth Hormone/metabolism , Humans , Hypothermia/blood , Hypothermia/physiopathology , Male , Presynaptic Terminals/metabolism , Prolactin/blood , Prolactin/metabolism , Receptors, Serotonin/metabolism , Receptors, Serotonin, 5-HT1 , Synaptic Membranes/drug effects , Synaptic Membranes/metabolism , Synaptic Transmission/drug effects , Synaptic Transmission/physiology , Tryptophan/deficiency
SELECTION OF CITATIONS
SEARCH DETAIL
...